edited on 02/02/2013:
AntriaBio, Inc. (“AntriaBio”) announced that FINRA has approved a change of the Company’s stock ticker symbol. Effective today, the Company’s common shares will commence trading on the OTC Bulletin Board under the trading symbol “ANTB” ( OTCQB : ANTB ). The previous trading symbol was “FMYY” ( OTCQB : FMYY ).
AntriaBio, Inc. (ANTB): mid-term investment opportunity with a potential (ROI) return on investment of 200%+
A Bit of History:
We profiled MRI Interventional (MRIC) in June last year. Our subscribers were first on a market to join MRIC stock at the rock-bottom prices. MRIC shares rose from $1.10 to over $4 per share in just a bit over of the four trading weeks. We expect that AntriaBio stock will even outperform MRIC’s run-up at the similar time-frame.
In January 7th, 2013, AntriaBio announced the acquisition of $100M+ in prior technology, formulation, manufacturing and intellectual property assets from PR Pharmaceuticals. Following this announcement, Fits My Style, Inc. (a.k.a. merger shell) completed the name change to AntriaBio and 1 to 6 forward split of its shares.
On January 11th, 2013, AntriaBio (FMYYD) stock has begun trading on the OTC Bulleting Board.
Market & Technology:
AntriaBio’s lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin. AB101 targets patients with type 1 and type 2 diabetes that require basal insulin for the control of hyperglycemia. Product allows to release insulin slowly over a period of one week without an adverse initial burst of insulin, thus offering a HUGE technology advantage to once-a-day insulin injections from the leading manufacturers such as Novo Nordisk (NYSE: NVO) & Sanofi-Aventis (NYSE: SNY). Furthermore, AntriaBio’s technology is compatible with other diabetes medications by sustained insulin level or may even complement effects from those medications.
From AntriaBio’s presentation at Biotech Showcase™ 2013 Conference in San Francisco:
- If approved, the Company believes that AB101 will result in greater patient convenience and compliance (once weekly delivery versus once daily delivery).
- Lantus, the bestselling basal insulin therapy offered by Sanofi-Aventis has sales annual in excess of $5B.
- Novo Nordisk’s basal insulin, Levemir, has $2B in annual sales.
- In North America, basal insulin commands a 47% share of total insulin usage. There is a significant opportunity for AB101 to enter new markets where basal insulin has limited penetration, including Europe (36%), Japan and Korea (29%), and China (13%).
The insulin segment of the U.S. diabetes drug market exceeded $12B in 2011. AntriaBio’s AB101 (if approved) has the potential to be a noteworthy player on this market with a product that represents a considerable advance in basal insulin delivery.
Simple math for the AB101 potentials (when approved): with $200MM in annual sales (very conservative estimate in comparison to $5B Lantus’ sales revenues) ANTB shares should be valued from 4X to 10X of their current market price.
Last, but not least: AntriaBio is a potential buy-out candidate even at its preclinical products development stages. The response on insulin injections for animals is identical to humans when those injections are administered in the right sequence. AB101 does not contain any new excipients, thus safety and efficacy data study could make the AB101 “approval-ready” & “buy-out ready” in just 18-24 months.
An affiliate of PennyStockHaven.com received twenty thousand dollars per month for providing consulting and advisory services to AntriaBio in the past and may receive cash and/or restricted stock in the future. This compensation may affect the objectivity of our profile of the company. PennyStockHaven.com own shares acquired in the open market and may sell these shares at any time. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.